Template:Clonidine: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
(2 intermediate revisions by 2 users not shown) | |||
Line 4: | Line 4: | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | CATAPRES<sup>®</sup> FDA Package Insert | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | CATAPRES<sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES indications and usage|Indications and Usage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES dosage forms and strengths|Dosage Forms and Strengths]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES contraindications|Contraindications]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES warnings and precautions|Warnings and Precautions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES adverse reactions|Adverse Reactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES drug interactions|Drug Interactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES use in specific populations|Use in Specific Populations]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES description|Description]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES clinical pharmacology|Clinical Pharmacology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES nonclinical toxicology|Nonclinical Toxicology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES clinical studies|Clinical Studies]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES how supplied storage and handling|How Supplied/Storage and Handling]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES patient counseling information|Patient Counseling Information]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CATAPRES labels and packages|Labels and Packages]] | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | CLONIDINE patch <sup>®</sup> FDA Package Insert | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | CLONIDINE patch <sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch indications and usage|Indications and Usage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch dosage forms and strengths|Dosage Forms and Strengths]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch contraindications|Contraindications]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch warnings and precautions|Warnings and Precautions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch adverse reactions|Adverse Reactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch drug interactions|Drug Interactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch use in specific populations|Use in Specific Populations]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch description|Description]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch clinical pharmacology|Clinical Pharmacology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch nonclinical toxicology|Nonclinical Toxicology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch clinical studies|Clinical Studies]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch how supplied storage and handling|How Supplied/Storage and Handling]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch patient counseling information|Patient Counseling Information]] | ||
|- | |- | ||
! style=" | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[CLONIDINE patch labels and packages|Labels and Packages]] | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | DURACLON (clonidine hydrochloride) injection<sup>®</sup> FDA Package Insert | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | DURACLON (clonidine hydrochloride) injection<sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON indications and usage|Indications and Usage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON dosage forms and strengths|Dosage Forms and Strengths]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON contraindications|Contraindications]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON warnings and precautions|Warnings and Precautions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON adverse reactions|Adverse Reactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON drug interactions|Drug Interactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON use in specific populations|Use in Specific Populations]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON description|Description]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON clinical pharmacology|Clinical Pharmacology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON nonclinical toxicology|Nonclinical Toxicology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON clinical studies|Clinical Studies]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON how supplied storage and handling|How Supplied/Storage and Handling]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON patient counseling information|Patient Counseling Information]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[DURACLON labels and packages|Labels and Packages]] | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Clonidine | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Clonidine | ||
Line 121: | Line 109: | ||
|- | |- | ||
|} | |} | ||